Department of Clinical Laboratory, Zhanjiang Central People's Hospital, Zhanjiang, Guangdong, China.
Clinical Research Institute, Zhanjiang Central People's Hospital, Zhanjiang, Guangdong, China.
Br J Hosp Med (Lond). 2024 Oct 30;85(10):1-13. doi: 10.12968/hmed.2024.0270. Epub 2024 Oct 23.
Lung cancer (LC) remains one of the most common malignant tumours worldwide, and assessment of its progression is important for ensuring better prognostic outcomes for patients. This study was designed to explore the prognostic role of certain indices, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) in patients with LC, to help clinics to better determine the prognosis of patients with LC, and to allow them to intervene in a timely manner. A retrospective analysis of 116 initially diagnosed patients with LC in China from 2018 to 2020 was conducted. The counts of neutrophils (NEU), lymphocytes (LYM), and monocytes (MON), as well as albumin levels, were obtained from laboratory databases. The PNI was calculated using a specific formula. The progression-free survival (PFS) curves were plotted using the Kaplan-Meier method, and the Log-rank test was used to compare survival among different groups. The potential prognostic role of these indicators was assessed with univariate and multivariate regression analysis. Multivariate Cox regression demonstrated that the PNI (hazard ratio (HR): 0.513, 95% confidence interval (CI): 0.288-0.917, = 0.024), NLR (HR: 2.038, 95% CI: 1.128-3.682, = 0.018), and tumour type (small cell lung cancer vs. non-small cell lung cancer) (HR: 2.145, 95% CI: 1.308-3.520, = 0.003) were significantly associated with PFS. The median PFS for patients with low and high PNI was 10 and 11.5 months, respectively. The NLR, PLR, and PNI are all significantly associated with the prognostic survival of LC patients.
肺癌（LC）仍然是全球最常见的恶性肿瘤之一，评估其进展对于确保患者获得更好的预后结果非常重要。本研究旨在探讨中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）和预后营养指数（PNI）等某些指标在 LC 患者中的预后作用，帮助临床医生更好地判断 LC 患者的预后，并及时进行干预。
对 2018 年至 2020 年在中国初诊的 116 例 LC 患者进行了回顾性分析。从实验室数据库中获得了中性粒细胞（NEU）、淋巴细胞（LYM）和单核细胞（MON）的计数以及白蛋白水平。使用特定公式计算 PNI。使用 Kaplan-Meier 方法绘制无进展生存期（PFS）曲线，并用对数秩检验比较不同组之间的生存情况。采用单因素和多因素回归分析评估这些指标的潜在预后作用。
多因素 Cox 回归分析表明，PNI（风险比（HR）：0.513，95%置信区间（CI）：0.288-0.917， = 0.024）、NLR（HR：2.038，95% CI：1.128-3.682， = 0.018）和肿瘤类型（小细胞肺癌与非小细胞肺癌）（HR：2.145，95% CI：1.308-3.520， = 0.003）与 PFS 显著相关。PNI 低和高的患者中位 PFS 分别为 10 个月和 11.5 个月。
NLR、PLR 和 PNI 均与 LC 患者的预后生存显著相关。
